Titlebook: Management of Pancreatic Cancer and Cholangiocarcinoma; Hiroyuki Isayama,Yousuke Nakai,Takashi Sasaki Book 2021 The Editor(s) (if applicab

交響樂

Detection Strategies and Examination of Early Pancreatic Cancerystic lesions in PC in situ, which is undetectable on cross-sectional images. Subsequently, ERCP and associated serial pancreatic juice aspiration cytologic examination obtained using endoscopic nasopancreatic drainage may be useful in the diagnosis of very early-stage PC. Additionally, collaboratio

導師

Biomarkers for Pancreatic Cancer and Cholangiocarcinomaests therapeutic targets in a timely manner. To date, no single marker has yet been approved for clinical use, with the exception of carbohydrate antigen 19-9, however, further advances in omics-based techniques and validation in large patient cohorts should result in the development of effective an

使虛弱

誤傳

Chemotherapy for Unresectable Cholangiocarcinoma the near future based on these results. Currently, combination therapies with various molecular-targeted drugs and immunotherapy are being investigated in several clinical trials, and it is expected that systemic therapy for advanced biliary tract cancer will become more diverse in the future as it

Substitution

Adjuvant Chemotherapy for Cholangiocarcinomaificant survival benefits, such as gemcitabine plus cisplatin and targeted molecular therapy against FGFR2 and IDH1 mutant tumors. Furthermore, immune checkpoint inhibitors have been evaluated as monotherapy or in combination with cytotoxic agents. These regimens are also candidates for testing in f

amenity

Neoadjuvant Therapy and Conversion Surgery for Cholangiocarcinoma cholangiocarcinoma have also suggested favorable results, although the definition of “unresectable locally advanced” remains unclear. Reports on conversion surgery in combination with chemotherapy for recurrent cholangiocarcinoma after surgery are scarce, but some long-term survivors after conversi

electrolyte

Keratin

albuminuria

cians, basic researchers and professionals at medical device and pharmaceutical companies broaden their understanding of the current treatment and management strategies for pancreatobiliary malignancies..978-981-16-2872-6978-981-16-2870-2

Insufficient